Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation

Arjun Gupta, Nivedita Arora, Waqas Haque, S. M.Qasim Hussaini, Ramy Sedhom, Anne H. Blaes, Stacie B. Dusetzina

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Article number101386
JournalJournal of Geriatric Oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 2023

Bibliographical note

Funding Information:
There are no conflicts of interest for any author. Dr. Dusetzina reported receiving grants from Arnold Ventures, the Commonwealth Fund, the Leukemia & Lymphoma Society, and the Robert Wood Johnson Foundation; receiving honoraria from West Health and the Institute for Clinical and Economic Review; and serving as a member of the Medicare Payment Advisory Commission and a consultant for the National Academy for State Health Policy outside the submitted work.

Keywords

  • Medication pricing
  • Oral drugs
  • Proportion

PubMed: MeSH publication types

  • Letter

Cite this